Here are four things to know:
1. Bio2 Technologies’ Vitrium, a resorbable orthobiologic material composed of bioactive glass.
2. The company will evaluate Vitrium as a structural device that facilitates bone remodeling through a gradual conversion from the device to the patient’s own bone. Vitrium is designed to be porous, load-bearing, osteoconductive and bioactive.
3. The investigational device exemption clinical study will assess Vitrium as a cervical interbody fusion device.
4. Paul K. Nichols, Jr., is the company’s president and CEO. He has 40 years of experience in the medical device industry, with30 years in the musculoskeletal sector.
More articles on biologics:
Spine biologics market to reach $2.72B by 2025 — 3 things to know
Vail-Summit Orthopaedics uses injectable treatments, biologics to expand care: 3 notes
Osiris Therapeutics appoints new CEO: 3 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
